Gemcitabine versus gemcitabine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: a retrospective analysis (Q33385864)

26 July 2017

title

Gemcitabine versus gemcitabine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: a retrospective analysis (English)

1 reference

26 July 2017

1 reference

1 reference

Jae-Hyuk Choi

1

1 reference

26 July 2017

Sung Yong Oh

2

1 reference

26 July 2017

Hyuk-Chan Kwon

3

1 reference

26 July 2017

Jung Hwan Kim

4

1 reference

26 July 2017

Jae Hoon Lee

5

1 reference

26 July 2017

Suee Lee

6

1 reference

26 July 2017

Dong Mee Lee

7

1 reference

26 July 2017

Sung-Hyun Kim

8

1 reference

26 July 2017

Myung Hwan Rho

9

1 reference

26 July 2017

Young-Hoon Kim

10

1 reference

26 July 2017

Mee-Sook Rho

11

1 reference

26 July 2017

Hyo-Jin Kim

12

1 reference

26 July 2017

publication date

31 March 2008

1 reference

Cancer Research and Treatment

26 July 2017

published in

1 reference

26 July 2017

volume

40

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

22-26

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

26 July 2017

copyright license

start time

31 March 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

Synergistic interaction between cisplatin and gemcitabine in vitro.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

Chemotherapy prolongs survival in inoperable pancreatic carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699081

Activity of cisplatin in adenocarcinoma of the pancreas

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19688061

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19688061

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4143/CRT.2008.40.1.22

1 reference

26 July 2017

1 reference

26 July 2017

1 reference